Venture capital's traditional "fund-returner" model is facing scrutiny in health tech, despite a market recovery seeing $7.4 billion raised in H1 2026. This funding is highly concentrated, with mega-rounds absorbing nearly half the capital, creating a "tale of two markets." Liquidity remains challenging, with no IPOs in H1 2026 and many mature companies facing an "exit backlog paradox." Investors like Dan Galles of Allumia Ventures note healthcare's inherent difficulties, including few new institutional customers and slow adoption. While private practices offer an entry, they are financially constrained. Self-insured employers and consumer-facing platforms prove more viable for scaling, exemplified by Hinge Health and Hims & Hers. AI offers promise but also benefits incumbents. Galles advocates for a new VC playbook, still pursuing billion-dollar exits but also enabling attractive $150M-$250M outcomes by focusing on early commercial adoption, efficient capital, and profitability, matching investment strategy to realistic exit potential. READ MORE